New-Onset Atrial Fibrillation After Exenatide Injection: Coincidence or Consequence?

Yamantuerk Y. Y., ESENBOĞA K., YILMAZ G. C., Baskovski E., CANDEMİR B., ŞAHİN M.

ENDOCRINOLOGY RESEARCH AND PRACTICE, vol.27, no.4, pp.241-244, 2023 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 4
  • Publication Date: 2023
  • Doi Number: 10.5152/erp.2023.23262
  • Journal Name: ENDOCRINOLOGY RESEARCH AND PRACTICE
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.241-244
  • Ankara University Affiliated: Yes

Abstract

The glucagon-like peptide 1 receptor agonists, together with sodium-glucose cotransporter-2 inhibi-tors, are antidiabetic drugs known for their beneficial effects on the cardiovascular system; many phase 3 trials also support this conclusion. However, it can be thought that they may cause an increase in the risk of tachyarrhythmia due to the stimulation of their receptors in the sympathetic nervous system and sinoatrial cells. We report a case of a 71-year-old woman with no history of arrhythmia who presented with new-onset atrial fibrillation after an exenatide injection during clinical follow-up.